Cereno Scientific signs CordenPharma to manufacture CS1 for “compassionate use” supply and for next clinical trial of CS1
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that an agreement has been signed with CordenPharma, a Contract Development and Manufacturing Organization (CDMO). CordenPharma is contracted to manufacture drug candidate CS1 in larger quantities, so-called scale-up manufacturing, needed to ensure supply to conduct the next clinical trial and later when approved for market launch. A request for Extended Access (also called “compassionate use”) for the use of CS1 is currently under